ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary (Q34248487)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

0 references

Bertram Wiedenmann

8

object named as

Bertram Wiedenmann

0 references

1 reference

ORCID Public Data File 2021

3

object named as

Anne Couvelard

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Eric P. Krenning

4

object named as

Eric Krenning

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Marianne Pavel

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Eric Baudin

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Kjell Öberg

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Thomas Steinmüller

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Martin Anlauf

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Ramon Salazar

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Barcelona Consensus Conference participants

10

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

15 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Neuroendocrinology

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

95

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

157-176

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Metastatic carcinoid tumor: changing patterns of care over two decades

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Surgery on neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Circulating markers for endocrine tumours of the gastroenteropancreatic tract

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Gastrinoma (duodenal and pancreatic).

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Well-differentiated pancreatic tumor/carcinoma: insulinoma

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Hereditary neuroendocrine tumors of the gastroenteropancreatic system

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Clinical utility of hybrid SPECT-CT in endocrine neoplasia

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Identification of unknown primary tumors in patients with neuroendocrine liver metastases.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/Carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Rare functioning pancreatic endocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Hepatic neuroendocrine metastases: does intervention alter outcomes?

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. treatment of hepatic metastases

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Hepatic surgery for metastases from neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Interventional treatment of gastrointestinal neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Neuroendocrine liver metastases

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

The small remnant liver after major liver resection: how common and how relevant?

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors?

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Trends and experiences in liver retransplantation over 15 years.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Liver transplantation for treatment of metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Indications and results of liver transplantation in patients with neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Liver ablation therapy

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Multiple fiber laser-induced thermotherapy for ablation of large intrahepatic tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Transcatheter chemoembolization of progressive carcinoid liver metastasis

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Ablative therapies for liver metastases of digestive endocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Transarterial Chemoembolization of Advanced Liver Metastases of Neuroendocrine Tumors – A Retrospective Single-Center Analysis

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Interferon in the management of neuroendocrine GEP-tumors: a review

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Glycemic control in patients with insulinoma treated with everolimus

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Malignant insulinomas with hepatic metastases successfully treated with selective internal radiation therapy

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Management of Intractable Hypoglycemia With Yttirum-90 Radioembolization in a Patient With Malignant Insulinoma

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

90Y-edotreotide for metastatic carcinoid refractory to octreotide

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Activity of sunitinib in patients with advanced neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Liver transplantation for neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

1 reference

https://api.crossref.org/works/10.1159%2F000335597

21 January 2018

Identifiers

10.1159/000335597

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34248487&oldid=2220959239"